BIONDVAX PHARMACEUTICALS-ADR (BVXV) Stock Price, Forecast & Analysis
USA - NASDAQ:BVXV - US09073Q2049 - ADR
BVXV Key Statistics, Chart & Performance
The current stock price of BVXV is 1.36 USD. In the past month the price increased by 2.26%. In the past year, price decreased by -87.02%.
BVXV Latest News, Press Relases and Analysis
BVXV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.55 | 3.94B |
Related stock screener links
About BVXV
Company Profile
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. BiondVax Pharmaceuticals Ltd core focus is to develop of NanoAbs for treatment of COVID-19, psoriasis and asthma. Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally the Company offers manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for other research and development companies. BiondVax Pharmaceuticals Ltd operates in Israel.
Company Info
BIONDVAX PHARMACEUTICALS-ADR
Jerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus
JERUSALEM 74036 IL
CEO: Amir Reichman
Employees: 33
Phone: 97289302529.0
BIONDVAX PHARMACEUTICALS-ADR / BVXV FAQ
Can you describe the business of BIONDVAX PHARMACEUTICALS-ADR?
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. BiondVax Pharmaceuticals Ltd core focus is to develop of NanoAbs for treatment of COVID-19, psoriasis and asthma. Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally the Company offers manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for other research and development companies. BiondVax Pharmaceuticals Ltd operates in Israel.
Can you provide the latest stock price for BIONDVAX PHARMACEUTICALS-ADR?
The current stock price of BVXV is 1.36 USD. The price increased by 3.82% in the last trading session.
Does BVXV stock pay dividends?
BVXV does not pay a dividend.
What is the ChartMill rating of BIONDVAX PHARMACEUTICALS-ADR stock?
BVXV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for BVXV stock?
BIONDVAX PHARMACEUTICALS-ADR (BVXV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.86).
Can you provide the market cap for BIONDVAX PHARMACEUTICALS-ADR?
BIONDVAX PHARMACEUTICALS-ADR (BVXV) has a market capitalization of 4.97M USD. This makes BVXV a Nano Cap stock.
BVXV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BVXV. When comparing the yearly performance of all stocks, BVXV is a bad performer in the overall market: 91.2% of all stocks are doing better.
BVXV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BVXV. BVXV has a bad profitability rating. Also its financial health evaluation is rather negative.
BVXV Financial Highlights
Over the last trailing twelve months BVXV reported a non-GAAP Earnings per Share(EPS) of -6.86. The EPS decreased by -93.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BVXV Forecast & Estimates
7 analysts have analysed BVXV and the average price target is 39.78 USD. This implies a price increase of 2825% is expected in the next year compared to the current price of 1.36.